Last reviewed · How we verify
Vivarin
At a glance
| Generic name | Vivarin |
|---|---|
| Also known as | 1,3,7-Trimethylpurine-2,6-dione, C8H10N4O2, caffeine citrate |
| Sponsor | King Saud University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Caracterization of the Combined Alterations in Respiration and aROUSal in Patients With Drug-resistant EpiLepsy (NA)
- Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart Failure (NYHA Class III-IV) (PHASE3)
- SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid (NA)
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) (PHASE2)
- Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance (NA)
- Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa (PHASE4)
- Improving Preterm Kidney Outcomes With Caffeine (PHASE2)
- Tritordeum-based Foods for IBS Symptoms (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |